Belinostat

Belinostat is a high-quality reference standard supplied with comprehensive characterization data, ensuring compliance with regulatory guidelines. This product is essential for analytical method development, method validation (AMV), quality control (QC) applications, and plays a crucial role in Abbreviated New Drug Applications (ANDA).

Belinostat can be used as a reference standard, with possible traceability to pharmacopeial standards such as USP or EP, based on feasibility. AquigenBio products are strictly for analytical purposes and is not intended for human use.

Applications of Belinostat:

1. Oncology Research and Drug Development

• Belinostat is an FDA-approved histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancers, particularly:

  • Peripheral T-cell lymphoma (PTCL)

  • Other hematologic malignancies and solid tumors (in clinical studies)

• Used to study epigenetic modulation in cancer cells, helping researchers explore gene expression regulation and tumor suppression mechanisms.

2. Pharmaceutical API Reference Standard

• Employed as a reference standard in the development, validation, and quality control of Belinostat-based pharmaceutical formulations.

• Utilized for:

  • Assay standardization

  • Impurity profiling

  • Stability testing

  • Method validation (HPLC, LC-MS/MS, etc.)

3. Epigenetic and Molecular Biology Research

• A key tool in epigenetic drug screening and mechanistic studies involving:

  • Chromatin remodeling

  • Cell cycle arrest

  • Apoptosis induction in tumor cells

• Facilitates research on the HDAC inhibition pathway, offering insights into cancer proliferation and differentiation.

4. Preclinical and Toxicological Studies

• Used in in vitro and in vivo studies for:

  • Evaluating anti-cancer activity

  • Assessing pharmacokinetics and pharmacodynamics

  • Understanding dose-response and toxicity profiles

5. Formulation Development and Analytical Testing

• Supports pharmaceutical R&D teams in designing oral or injectable dosage forms.

• Helps in:

  • Developing bioanalytical methods for pharmacokinetic studies

  • Forced degradation and stability-indicating studies

  • Establishing analytical quality-by-design (AQbD) approaches

6. Clinical Research Applications

• Belinostat is investigated in combination therapies with other chemotherapeutic agents, immunotherapies, or targeted therapies.

• Supports studies aiming to:

  • Enhance therapeutic efficacy

  • Overcome drug resistance in cancers

  • Personalize cancer treatment based on epigenetic markers

⚠️ Note: Belinostat is a potent antineoplastic agent. It must be handled by trained professionals with appropriate safety precautions. Intended for research and pharmaceutical use only — not for human or veterinary consumption without regulatory approval.